Previous 10 | Next 10 |
NEW YORK, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the t...
Y-mAbs Therapeutics ( NASDAQ: YMAB ) said on Monday its partner Adium Pharma S.A. had submitted a regulatory filing for the approval of Danyelza to treat relapsed/refractory high-risk neuroblastoma to the Brazilian Health Regulatory Agency. The comp...
NEW YORK, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today annou...
NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the ...
NEW YORK and PETAH TIKVA, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therape...
Y-mAbs Therapeutics, Inc. (YMAB) Q2 2022 Results Conference Call August 9, 2022 9:00 AM ET Company Participants Thomas Gad - Founder, Interim CEO and President Bo Kruse - CFO Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Con...
The following slide deck was published by Y-mAbs Therapeutics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Y-mAbs Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation
Y-mAbs Therapeutics press release ( NASDAQ: YMAB ): GAAP EPS of -$0.94 (vs. -$0.53 Y/Y) misses by $0.29 . Revenue of $10.8M (-1.8% Y/Y) misses by $0.42M . Management reiterates all elements of its financial guidance including: DANYELZA® 2022 revenu...
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter that ended June 30, 2022, on Monday, August 8, 2022, after the close of the ...
Y-mAbs Therapeutics ( NASDAQ: YMAB ) said the U.S. Food and Drug Administration (FDA) cleared its application to start a phase 1 multicenter basket trial for GD2-SADA targeting malignant melanoma, sarcoma and small cell lung cancer. The trial will have three parts and ...
News, Short Squeeze, Breakout and More Instantly...
Y-mAbs Therapeutics Inc. Company Name:
YMAB Stock Symbol:
NASDAQ Market:
Y-mAbs Therapeutics Inc. Website:
2024-07-05 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic pr...
Q1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022 Management updates 2023 financial guidance, now anticipating higher DANYELZA net revenues of $80-85 million and lower cash burn of $40-50 millio...